Association of chronic GVHD initial therapy and FFS
| Factor . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | Global P . | HR (95% CI) . | P . | Global P . | |
| Initial therapy group | 0.09 | .22 | ||||
| Prednisone only | Reference | Reference | ||||
| Nonprednisone | 0.95 (0.75, 1.20) | .66 | 0.97 (0.75, 1.24) | .78 | ||
| Prednisone + other agent(s) | 0.80 (0.65, 0.98) | .03 | 0.82 (0.65, 1.03) | .09 | ||
| Platelets ≥ 100 (onset) | 0.81 (0.65, 1.01) | .06 | 0.78 (0.61, 0.99) | .04 | ||
| Gastrointestinal | .04 | .04 | ||||
| Not involved | Reference | Reference | ||||
| Mild | 1.30 (1.06, 1.60) | .01 | 1.31 (1.06, 1.63) | .01 | ||
| Moderate/severe | 1.13 (0.86, 1.50) | .38 | 0.98 (0.72, 1.33) | .89 | ||
| Eye | .02 | .02 | ||||
| Not involved | Reference | Reference | ||||
| Mild | 0.79 (0.65, 0.96) | .02 | 0.79 (0.64, 0.96) | .02 | ||
| Moderate/severe | 0.72 (0.54, 0.98) | .04 | 0.69 (0.50, 0.96) | .03 | ||
| Lung | .07 | .29 | ||||
| Not involved | Reference | Reference | ||||
| Mild | 1.13 (0.89, 1.44) | .31 | 1.20 (0.92, 1.55) | .18 | ||
| Moderate/severe | 1.52 (1.04, 2.21) | .03 | 1.22 (0.80, 1.86) | .35 | ||
| NIH stage | .10 | .07 | ||||
| Less than mild/mild | Reference | Reference | ||||
| Moderate | 1.08 (0.86, 1.36) | .49 | 1.13 (0.87, 1.47) | .35 | ||
| Severe | 1.29 (1.00, 1.65) | .05 | 1.39 (1.04, 1.87) | .03 | ||
| Site | .07 | |||||
| FHCRC | Reference | .02 | Reference | |||
| Dana Farber Cancer Institute | 1.30 (0.98, 1.72) | .06 | 1.30 (0.94, 1.79) | .11 | ||
| Moffitt Cancer Center | 1.27 (0.85, 1.90) | .24 | 1.13 (0.73, 1.76) | .58 | ||
| Stanford University | 1.06 (0.77, 1.44) | .73 | 1.16 (0.83, 1.62) | .38 | ||
| University of Minnesota | 0.98 (0.73, 1.31) | .88 | 0.94 (0.68, 1.28) | .68 | ||
| Vanderbilt University | 0.99 (0.72, 1.36) | .95 | 0.93 (0.66, 1.30) | .67 | ||
| Other* | 1.60 (1.22, 2.11) | .001 | 1.55 (1.15, 2.10) | .004 | ||
| Year chronic GVHD > 2012 | 1.17 (0.98, 1.40) | .08 | 1.18 (0.97, 1.43) | .09 | ||
| Factor . | Univariate . | Multivariate . | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | Global P . | HR (95% CI) . | P . | Global P . | |
| Initial therapy group | 0.09 | .22 | ||||
| Prednisone only | Reference | Reference | ||||
| Nonprednisone | 0.95 (0.75, 1.20) | .66 | 0.97 (0.75, 1.24) | .78 | ||
| Prednisone + other agent(s) | 0.80 (0.65, 0.98) | .03 | 0.82 (0.65, 1.03) | .09 | ||
| Platelets ≥ 100 (onset) | 0.81 (0.65, 1.01) | .06 | 0.78 (0.61, 0.99) | .04 | ||
| Gastrointestinal | .04 | .04 | ||||
| Not involved | Reference | Reference | ||||
| Mild | 1.30 (1.06, 1.60) | .01 | 1.31 (1.06, 1.63) | .01 | ||
| Moderate/severe | 1.13 (0.86, 1.50) | .38 | 0.98 (0.72, 1.33) | .89 | ||
| Eye | .02 | .02 | ||||
| Not involved | Reference | Reference | ||||
| Mild | 0.79 (0.65, 0.96) | .02 | 0.79 (0.64, 0.96) | .02 | ||
| Moderate/severe | 0.72 (0.54, 0.98) | .04 | 0.69 (0.50, 0.96) | .03 | ||
| Lung | .07 | .29 | ||||
| Not involved | Reference | Reference | ||||
| Mild | 1.13 (0.89, 1.44) | .31 | 1.20 (0.92, 1.55) | .18 | ||
| Moderate/severe | 1.52 (1.04, 2.21) | .03 | 1.22 (0.80, 1.86) | .35 | ||
| NIH stage | .10 | .07 | ||||
| Less than mild/mild | Reference | Reference | ||||
| Moderate | 1.08 (0.86, 1.36) | .49 | 1.13 (0.87, 1.47) | .35 | ||
| Severe | 1.29 (1.00, 1.65) | .05 | 1.39 (1.04, 1.87) | .03 | ||
| Site | .07 | |||||
| FHCRC | Reference | .02 | Reference | |||
| Dana Farber Cancer Institute | 1.30 (0.98, 1.72) | .06 | 1.30 (0.94, 1.79) | .11 | ||
| Moffitt Cancer Center | 1.27 (0.85, 1.90) | .24 | 1.13 (0.73, 1.76) | .58 | ||
| Stanford University | 1.06 (0.77, 1.44) | .73 | 1.16 (0.83, 1.62) | .38 | ||
| University of Minnesota | 0.98 (0.73, 1.31) | .88 | 0.94 (0.68, 1.28) | .68 | ||
| Vanderbilt University | 0.99 (0.72, 1.36) | .95 | 0.93 (0.66, 1.30) | .67 | ||
| Other* | 1.60 (1.22, 2.11) | .001 | 1.55 (1.15, 2.10) | .004 | ||
| Year chronic GVHD > 2012 | 1.17 (0.98, 1.40) | .08 | 1.18 (0.97, 1.43) | .09 | ||
Other factors investigated but not found to be related to FFS include initial steroid dose, age at cGVHD diagnosis, sex, disease, myeloablative conditioning, transplant source, donor age, match type and relation, time from transplant to chronic diagnosis, prior acute GVHD, KPS at cGVHD onset, bilirubin at cGVHD onset, organ scores for skin, mouth, joint, genital, and liver, and cGVHD overlap vs acute.
Includes Roswell Park Cancer Institute, Cleveland Clinic, University of British Columbia, Duke University, MD Anderson, NW Children’s, Medical College of Wisconsin, Washington University, MSK, Mayo Clinic, UNC, and Weill Cornell Medical College.